Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.

MLA

Antonarakis, Emmanuel S., et al. “Phase I Rapid Dose-Escalation Study of AGS-1C4D4, a Human Anti-PSCA (Prostate Stem Cell Antigen) Monoclonal Antibody, in Patients with Castration-Resistant Prostate Cancer: A PCCTC Trial.” Cancer Chemotherapy and Pharmacology, vol. 69, no. 3, Mar. 2012, pp. 763–71. EBSCOhost, https://doi.org/10.1007/s00280-011-1759-9.

APA

Antonarakis, E. S., Carducci, M. A., Eisenberger, M. A., Denmeade, S. R., Slovin, S. F., Jelaca-Maxwell, K., Vincent, M. E., Scher, H. I., & Morris, M. J. (2012). Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemotherapy and Pharmacology, 69(3), 763–771. https://doi.org/10.1007/s00280-011-1759-9

Chicago

Antonarakis, Emmanuel S, Michael A Carducci, Mario A Eisenberger, Samuel R Denmeade, Susan F Slovin, Kathy Jelaca-Maxwell, Martha E Vincent, Howard I Scher, and Michael J Morris. 2012. “Phase I Rapid Dose-Escalation Study of AGS-1C4D4, a Human Anti-PSCA (Prostate Stem Cell Antigen) Monoclonal Antibody, in Patients with Castration-Resistant Prostate Cancer: A PCCTC Trial.” Cancer Chemotherapy and Pharmacology 69 (3): 763–71. doi:10.1007/s00280-011-1759-9.